Ignite Creation Date:
2024-05-06 @ 1:39 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04082364
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2019-09-05
Brief Title:
Combination Margetuximab Retifanlimab Tebotelimab and Chemotherapy Phase 23 Trial in HER2 GastricGEJ Cancer
Sponsor:
MacroGenics
Organization:
MacroGenics
Organization Data
Organization:
MacroGenics
Class:
INDUSTRY
Study ID:
CP-MGAH22-06
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MacroGenics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Zai Lab Shanghai Co Ltd | INDUSTRY |